Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant (YOH1)

Anders Rosengren, MD PhD

Status and phase: Completed; Phase 2

Conditions: Type 2 Diabetes

Treatments: Drug: Yohimbine

Study type: Interventional

Funder types: Other

Identifiers

NCT01593215

2010-018604-85

Details and patient eligibility

About

The investigators have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes. The investigators have also seen that blockers of that receptor improves impaired insulin secretion in animals. The investigators will now test the blocker in patients with type 2 diabetes with or without the risk variant in an effort to make diabetes treatment more individualized.

Full description

We have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes. We have also seen that blockers of that receptor improves impaired insulin secretion in animals. We will now test the blocker in patients with type 2 diabetes with or without the risk variant in an effort to make diabetes treatment more individualized. Patients will receive two different doses of the blocker and the effect will be measured with oral glucose tolerance tests. The study is a randomized placebo-controlled study.

Enrollment: 50 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type 2 diabetes
• informed consent
• age 18-70, for females only postmenopausal

Exclusion criteria

• heart disease
• anxiety disorder
• antidiabetic treatment other than metformin
• adrenergic blockers
• ulcus
• allergy to any component in the capsules

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups

Placebo first then yohimbine

Active Comparator group

Description:

placebo first, then yohimbine

Treatment:

Drug: Yohimbine

Yohimbine first then placebo

Active Comparator group

Description:

Yohimbine first then placebo

Treatment:

Drug: Yohimbine